

Ingrid D. Peterson, PhD, MPH

ipeterson@lux-medcom.com

<https://luxmedicalcommunications.com/>

<https://www.linkedin.com/in/ingrid-peterson-95686b12b/>

SKILLS

- Expert writing of peer-reviewed manuscripts, protocols, slide decks, and more
- Strong understanding of data analysis and the clinical research process
- Extensive experience in managing client relationships
- Solid knowledge of the AMA Manual of Style and good publication practice guidelines

PROPRIETARY FREELANCE PROJECTS

- Publications: Lead writer on peer-reviewed manuscripts, conference posters, and slide shows
- Regulatory: CSRs, IBs, SAPs
- Continuing Medical Education: slide shows, manuscripts, and animation scripts
- B2B content: white papers, blogs, and dossiers for pharmaceutical and medical device companies

SELECTED PUBLICATIONS (of 35, 7 as first author)

1. **Peterson I**, Bar-Zeev N, Kennedy N, Ho A, Newberry L, San Joaquin M, et al. Respiratory virus-associated SARI in African children in a setting with a high prevalence of HIV, malaria and malnutrition. *J Infect Dis.* 2016;214(11).
2. **Peterson I**, Ming D, Kelly C, Malisita K, Mallewa J, Mwandumba H, et al. Unstructured treatment interruption is a prevalent and important risk factor for arterial stiffness in an adult Malawian ART patient cohort. *AIDS.* 2016;30:2373–2378.
3. **Peterson I**, Ntusi N, Jambo K, Kelly C, Huwa J, Afran L, et al. Evaluating the reactivation of herpesviruses and inflammation as cardiovascular and cerebrovascular risk factors in antiretroviral therapy initiators in an African HIV-infected population (RHICCA): a protocol for a longitudinal cohort study. *BMJ Open.* 2019; 9(9): e025576

LEAD WRITER ON FUNDED RESEARCH GRANTS

Co-Principal Investigator /Lead Writer: ‘The identification of modifiable viral and inflammatory risk factors for cerebrovascular and cardiovascular disease in HIV-infected Malawian adults’ GlaxoSmithKline, Total Direct Costs: £875,976; <https://doi.org/10.1186/ISRCTN42862937>

Principal-Investigator/ Lead Writer: ‘A non-randomized immunogenicity trial of a World Health Organization Pre-qualified Inactivated Influenza Vaccine (IIV) in children age 6 to 59 months residing in a malaria endemic area of Malawi, Centers for Disease Control, 1U01IP000848-01, Total Direct Costs: \$1,125,000; Trial registration: <https://doi.org/10.1186/ISRCTN51364654>

SELECTED BLOGS POSTS

1. “An Epilepsy DTx can Achieve Better Patient Outcomes. Here’s how.” Jun 7, 2022
<https://www.sidekickhealth.com/news/epilepsy-dtx-achieve-better-patient-outcomes>
2. “Breast Cancer Patients Need Psychosocial Support—A DTx Solution can Help” May 16, 2022
<https://www.sidekickhealth.com/news/breast-cancer-psychosocial-support-dtx>
3. “Can a Cloned Rotavirus Shell Make for a More Effective Vaccine?” May 16, 2019;
<https://www.defeatdd.org/blog/can-cloned-rotavirus-shell-make-more-effective-vaccine>

MEMBERSHIPS & CERTIFICATIONS

Since 2019	American Medical Writers Association
Since 2023	National Association of Medical Writers
Since 2021	Editorial Board of <i>AIDS</i>
2016 & 2017	Certification in SAS Programming (Base, Advanced, and Clinical Trials)

EDUCATION

2000-2006	PhD	Epidemiology, Columbia University, New York
1996-1998	MPH	Epidemiology/Biostatistics, University of California, Berkeley

WRITING COURSES

2020-present	UCSD Certificate Program in Medical Writing
Feb-Mar 2021	LearnAMASyle.com

EMPLOYMENT SINCE 2010

Freelance Medical Writer and Editor (June 2017-present)

Assistant Professor (Nov 2017-Nov 2020)

Department of Pediatrics, University of Maryland School of Medicine, Baltimore

Lecturer in Epidemiology (Jan 2013-Nov 2017)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK

Research Associate (Sep 2012-Dec 2012)

Management and Development for Health, Harvard University, Boston

Study Director HIV Incidence Measurement Study (Nov 2010-Aug 2012)

ICAP, Columbia University, New York